# Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

> **NCT06209294** · PHASE2 · RECRUITING · sponsor: **Xiaohua Wu** · enrollment: 30 (estimated)

## Conditions studied

- Neoadjuvant Immunotherapy
- Cervical Cancer
- Fertility-sparing Surgery

## Interventions

- **DRUG:** AK104
- **DRUG:** Carboplatin
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT06209294
- **Lead sponsor:** Xiaohua Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06209294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06209294, "Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06209294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*